SCHEMBL16013918

SCHEMBL16013918

O=C(c1nc2c(Nc3ccc4[nH]c(=O)sc4c3)ncnc2s1)N1CCCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 19/20 1.00
▸ GRM4 Q14833 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16014831 0.84 MKNK1 (1.00) MKNK1
SCHEMBL16013395 0.81 MKNK1 (1.00) MKNK1
SCHEMBL15618333 0.80 MKNK1 (0.66) MKNK1GRM4
SCHEMBL15618498 0.78 MKNK1 (0.64) MKNK1GRM4
SCHEMBL16372229 0.77 MKNK1 (0.80) MKNK1
SCHEMBL16013830 0.77 MKNK1 (1.00) MKNK1
SCHEMBL16013306 0.76 MKNK1 (1.00) MKNK1
SCHEMBL16013494 0.76 MKNK1 (1.00) MKNK1
SCHEMBL16013831 0.76 MKNK1 (0.66) MKNK1
SCHEMBL16013307 0.75 MKNK1 (0.64) MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9675612-B2 Substituted thiazolopyrimidines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-06-13 — — US claimed
US-20160009734-A1 SUBSTITUTED THIAZOLOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-01-14 — — US claimed
US-9675612-B2 Substituted thiazolopyrimidines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-06-13 — — US disclosed
US-9675612-B2 Substituted thiazolopyrimidines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-06-13 — — US disclosed
US-20160009734-A1 SUBSTITUTED THIAZOLOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-01-14 — — US disclosed
US-20160009734-A1 SUBSTITUTED THIAZOLOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-01-14 — — US disclosed
EP-2964656-A1 SUBSTITUTED THIAZOLOPYRIMIDINES Bayer Pharma Aktiengesellschaft (DE) 2016-01-13 — — EP disclosed
WO-2014135480-A1 SUBSTITUTED THIAZOLOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-09-12 — — WO disclosed
WO-2014135480-A1 SUBSTITUTED THIAZOLOPYRIMIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-09-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009734-A1 SUBSTITUTED THIAZOLOPYRIMIDINES DPYD, TYMP, THPO MKNK1 3409/4885GRM4 4704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback